POSTED: November 14, 2014

NEW YORK CITY, October 14, 2014 – - It happens all too often; people struck by a “silent killer” that can leave them with permanent disabilities or dead. That silent killer is stroke and each year there are an estimated 750,000 acute ischemic strokes in the United States and more than two million worldwide. What’s troubling is that just three to five percent of stroke victims receive pharmacologic treatment because of risks associated with current therapies.

Zocere, Inc., a New Mexico-based pharmaceutical company believes it has a solution for this global health threat: a biologic-based “brain saving” drug for ischemic stroke that has the potential to become the first neuroprotectant on the market. Zocere CEO Wayne Laslie is presenting the drug at the Life Sciences Summit being held in New York City October 28 and 29.

The Life Sciences Summit is an early stage investor and business development conference that highlights innovation. The event connects biotech and academic innovators with the capital and strategic partners they need to move new discoveries into clinical development. The two-day program features corporate presentations by promising young companies with transformative science that targets unmet medical needs and that have raised $15 million or less with pre-clinical to Phase 2A assets.

Zocere’s drug is based on a STEP protein, a cell-permeable, recombinant peptide, that shows promise as a potent “brain saving” drug when administered post stroke. It also holds the potential for treating other brain trauma, including concussion. Zocere has exclusive, global rights to the patent-pending technology, and has succeeded in raising a half million dollars. Zocere is seeking capital investment of $1 million to $1.5 million in exchange for equity in the company. These funds will further development up to the Investigational New Drug (IND) process.

Laslie, a pharmaceutical professional with more than 30 years of experience in pharmaceutical commercialization in U.S. and international markets, believes his company’s drug, which protects the brain post stroke, is the transformative technology the healthcare industry and investors seek. “People can relate to stroke as it touches so many lives. One doesn’t have to work in health care to know there is a great unmet need in stroke therapeutics. Zocere is working to be that solution.”